Loren Lasko

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Loren Lasko, Clarissa G. Jakob, Rohinton Edalji et al. · Nature · 2017 · 813 citations · Full text

Lineage-specific Tumours, Medicine, Immune Checkpoint Inhibitor +8

ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

Cherrie K. Donawho, Yan Luo, Yanping Luo et al. · Clinical Cancer Research · 2007 · 762 citations · Full text

ABT-888 Confers Broad <i>In vivo</i> Activity in Combination with Temozolomide in Diverse Tumors

Joann P. Palma, Yichun Wang, Luis E. Rodrı́guez et al. · Clinical Cancer Research · 2009 · 138 citations

The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity

Kenneth D. Bromberg, Taylor R. H. Mitchell, Anup K. Upadhyay et al. · Nature Chemical Biology · 2017 · 127 citations · Full text

Chromatin, Chromatin Remodeling, Epigenetic Change +10

Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways

Xuesong Liu, Edward K. Han, Mark G. Anderson et al. · Molecular Cancer Research · 2009 · 91 citations

Abt-888 Is, Genetics, Molecular Biology +24